The consultant's guide to smoldering multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma (MM).
• SMM prevalence increases with age and is higher in men.
• Diagnosis requires excluding myeloma-defining events and risk stratification.

Purpose of the Study:

• To evaluate the potential benefit of early treatment initiation in high-risk smoldering multiple myeloma.
• To review risk stratification models and clinical trials in SMM management.
• To discuss the evolving clinical management of SMM patients.

Main Methods:

• Review of two randomized clinical trials investigating early treatment for SMM.
• Analysis of risk stratification models for SMM progression.
• Discussion of current and ongoing SMM treatment trials.

Main Results:

• Two clinical trials demonstrated clinical benefit from initiating treatment at the SMM stage.
• One trial showed an overall survival advantage for patients treated early.
• Risk stratification is crucial for identifying patients who may benefit from early intervention.

Conclusions:

• While monitoring is standard, early treatment may be beneficial for select high-risk SMM patients.
• Evidence suggests potential survival benefits from treating SMM before progression to active MM.
• Further research and clinical trials are ongoing to refine SMM management strategies.